Everolimus for Advanced Pancreatic Neuroendocrine Tumors

Abstract

Everolimus, as compared with placebo, significantly prolonged progression-free survival among patients with progressive advanced pancreatic neuroendocrine tumors and was associated with a low rate of severe adverse events. (Funded by Novartis Oncology; RADIANT-3 ClinicalTrials.gov number, NCT00510068.).

References

Page 1

	Year	Citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Toxicity and response criteria of the Eastern Cooperative Oncology Group Martin M. Oken, Richard H. Creech, Douglass C. Tormey, American Journal of Clinical Oncology Health SciencesMedicineCancer ManagementClinical EndpointPharmacology	1982	11.4K
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Robert J. Motzer, Bernard Escudier, Stéphane Oudard, The Lancet UrologySurgical OncologyGenitourinary CancerMedicineCancer Treatment	2008	3K
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul, New England Journal of Medicine	2011	2.5K
Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma Charles G. Moertel, Myrto Lefkopoulo, Stuart R. Lipsitz, New England Journal of Medicine	1992	969
Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma Charles G. Moertel, James A. Hanley, Lewis A. Johnson New England Journal of Medicine	1980	651
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial James C. Yao, Catherine Lombard‐Bohas, Éric Baudin, Journal of Clinical Oncology Octreotide LarSurgical OncologyPancreatic CancerPhase Ii TrialGastrointestinal Oncology	2009	648
Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study James C. Yao, Alexandria T. Phan, David Z. Chang, Journal of Clinical Oncology	2008	645
Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas Maria A. Kouvaraki, Jaffer A. Ajani, Paulo M. Hoff, Journal of Clinical Oncology	2004	605
Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway Edoardo Missiaglia, Irene Dalai, Stefano Barbi, Journal of Clinical Oncology	2009	533

Page 1